Celcuity Inc. (CELC)

NASDAQ: CELC · IEX Real-Time Price · USD
10.25
-0.11 (-1.01%)
Mar 31, 2023, 4:00 PM EDT - Market closed
-1.01%
Market Cap 222.32M
Revenue (ttm) n/a
Net Income (ttm) -40.37M
Shares Out 21.69M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 303,443
Open 10.31
Previous Close 10.36
Day's Range 10.16 - 10.86
52-Week Range 4.81 - 14.40
Beta 0.63
Analysts Buy
Price Target 25.16 (+145.46%)
Earnings Date May 15, 2023

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with horm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 39
Stock Exchange NASDAQ
Ticker Symbol CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CELC stock is "Buy." The 12-month stock price forecast is $25.16, which is an increase of 145.46% from the latest price.

Price Target
$25.16
(145.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025 Updat...

1 week ago - Accesswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w...

2 weeks ago - Accesswire

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publicati...

2 weeks ago - Accesswire

Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its partic...

1 month ago - Accesswire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE...

1 month ago - Accesswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...

3 months ago - PRNewsWire

Celcuity Closes $100 Million Private Placement

MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceed...

3 months ago - Accesswire

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation status Median progression free survival (PFS) of 42.3 months was repo...

4 months ago - Accesswire

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan tranche MINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clini...

4 months ago - Accesswire

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announce...

4 months ago - Accesswire

Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

MINNEAPOLIS, MN / ACCESSWIRE / November 10, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, t...

5 months ago - Accesswire

Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Completed selection of 200 clinical trial sites for the Phase 3 VIKTORIA-1 breast cancer study; activated first clinical trial site in the third quarter; expect dosing of first patient by year-end Upd...

5 months ago - Accesswire

Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, tod...

5 months ago - Accesswire

Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancer Entered into agreements for the private placement sale of $100 million of equity and to increase...

8 months ago - Accesswire

Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / August 4, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today an...

8 months ago - Accesswire

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

MINNEAPOLIS, MN / ACCESSWIRE / August 3, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today an...

8 months ago - Accesswire

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today ann...

9 months ago - Accesswire

Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet

The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

10 months ago - Zacks Investment Research

Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, th...

10 months ago - Zacks Investment Research

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pati...

11 months ago - Accesswire

Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Man...

11 months ago - Accesswire

Celcuity Inc. Announces $100 Million Private Placement

Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-...

11 months ago - Accesswire

Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patie...

11 months ago - Accesswire

Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pat...

1 year ago - Accesswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer Presented updated Phase 1b data duri...

1 year ago - Accesswire